GlassScriptPhysician profile
Jonathan David Frank
NPI 1215003090
$11,752.16
in general payments reported to CMS, 2019-2025
33 companies · $42.68 in 2025
The $42.68 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,674 · 2020: $709 · 2021: $1,000 · 2022: $616 · 2023: $577 · 2024: $133 · 2025: $42.68.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $753.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $753.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Linvatec Corporation | $7,003.84 | 2019 | |
| Janssen Pharmaceuticals, INC | $1,281.00 | 2019-2022 | |
| Pfizer INC. | $1,021.02 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $412.46 | 2021-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Sunovion Pharmaceuticals INC. | $225.40 | 2019-2020 | |
| Amgen INC. | $219.14 | 2019 | |
| Novartis Pharmaceuticals Corporation | $198.68 | 2019-2022 | |
| Anika Therapeutics, INC. | $195.34 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $164.92 | 2019-2023 | Eliquis |
| Almatica Pharma LLC | $143.19 | 2023 | Loreev Xr, Gralise, Sertraline Hcl |
| Astellas Pharma US INC | $139.70 | 2019-2023 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.68 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $76.04 | 2023-2024 | Gemtesa |
| Glaxosmithkline, LLC. | $49.27 | 2023 | Arexvy |
| Ucb, INC. | $44.43 | 2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $43.33 | 2020-2021 | |
| Lilly USA, LLC | $43.27 | 2019-2020 | |
| Globus Medical, INC. | $42.68 | 2025 | Senza |
| Biohaven Pharmaceutical Holding Company LTD. | $42.56 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $41.49 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $37.96 | 2019 | |
| Aimmune Therapeutics, INC. | $22.55 | 2024 | |
| Amneal Pharmaceuticals LLC | $20.78 | 2022 | |
| Boston Scientific Corporation | $19.95 | 2021 | |
| Avanir Pharmaceuticals, INC. | $18.80 | 2021 | |
| Daiichi Sankyo INC. | $17.66 | 2019 | |
| Ferring Pharmaceuticals INC. | $17.24 | 2019 | |
| Nestle Healthcare Nutrition INC. | $16.94 | 2023 | |
| Vertiflex, INC. | $16.52 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.45 | 2024 | Rexulti |
| Abbvie INC. | $15.22 | 2021 | |
| Sanofi Pasteur INC. | $14.38 | 2019 | |
| Vivus LLC | $5.27 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Frank listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.